Navigation Links
Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
Date:11/16/2007

ticipating in assessing bavituximab have extensive experience in conducting mid and late stage cancer studies that adhere to FDA and international standards, and we look forward to working with them to ensure the timely conduct of this important Phase II trial."

Tumor response in this new study will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) parameters. The trial is being conducted according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) standards.

According to the World Health Organization, metastatic breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths. The National Cancer Institute estimates that 178,480 U.S. women will be diagnosed with cancer of the breast in 2007 and 40,460 women will die of the disease.

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is usually located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase lb trial in advanced cancer patients, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. A protocol for a Phase II trial of bavituximab in combination with the chemotherapy drugs paclitaxel and carboplatin in patients with metastatic breast cancer is currently undergoing regulatory review in India. A protocol for a Phase II trial of bavituximab in combination with the chemotherapy drugs paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) is also under regulatory rev
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... California (PRWEB) April 20, 2015 At ... Entertainment held the “RockNRolla Movie Awards” EcoLuxe Lounge, with ... Los Angeles’ leading producer of sustainable product placement in ... providers of socially conscious and ecologically sound goods and ... film star Chase Masterson hosted the Choices Celebrity Interview ...
(Date:4/20/2015)... 2015 Goodreads is sponsoring a book ... It’s Good for You and Your Company between Mar. ... and Rick Lindquist have released a new book ... Good for You and Your Company. The book discusses ... woes - employer-funded individual health insurance. , According ...
(Date:4/20/2015)... Early registration is open for the ... space at the start line. Returning to James Kealoha ... limited to 500 participants (actually there’s only 499 spots since ... , Now thru April 30, the entry fee is only ... May 1st, the fee goes up to $200 and $100, ...
(Date:4/20/2015)... TROY Healthcare Solutions will be hosting an ... which provides the ultimate level of security for prescriptions, ... Anthem Suite Hotel in the Socrates Room, located at ... Beginning at 7 AM, TROY Healthcare Solutions will host ... Solutions will offer brief 15-20 minute presentations each hour ...
(Date:4/20/2015)... (PRWEB) April 20, 2015 "It's so ... done for our family. Initially, I really thought I ... it would end. But what I've discovered is this ... to be together, support each other and walk through ... Keller. "I have learned way more from these families ...
Breaking Medicine News(10 mins):Health News:Choices Recovery South Bend Talks About Healthy Decisions with TV's Adrienne Janic 2Health News:Zane Benefits Announces Complimentary Book Giveaway On GoodReads: The End of Employer-Provided Health Insurance: Why It's Good for You and Your Company 2Health News:Zane Benefits Announces Complimentary Book Giveaway On GoodReads: The End of Employer-Provided Health Insurance: Why It's Good for You and Your Company 3Health News:Hilo Triathlon Kicks Up Its Heels A Second Time; Early Bird Registration Available Online Now. 2Health News:Hilo Triathlon Kicks Up Its Heels A Second Time; Early Bird Registration Available Online Now. 3Health News:TROY Healthcare to Offer Prescription Solutions that Could Save a Health System $100,000 2Health News:TROY Healthcare to Offer Prescription Solutions that Could Save a Health System $100,000 3Health News:3 Years Later, Ramsey Keller Memorial Founder Reflects on Baby Loss, Giving Back by Paying for Infant Funerals in Montana and Receiving More Than She Will Ever Give 2Health News:3 Years Later, Ramsey Keller Memorial Founder Reflects on Baby Loss, Giving Back by Paying for Infant Funerals in Montana and Receiving More Than She Will Ever Give 3
... What: Sacramento - On Tuesday, April 28, at 1:30 p.m., Donate, ... press conference to announce, Padilla,s ... grade health classes to include 15 minutes of education regarding, ... bill ultimately, would provide California ...
... total $36.1 million, an increase of 22% over 2007- ... for the fourth quarter, $14.4 million for the full ... (Nasdaq: ENCO ), a full service ... and management capabilities for clinical trials and patient registries ...
... Life Sciences Inc. ("Bioniche"; TSX: BNC), a research-based, ... on its corporate activities. , One of the ... previous financial disclosures, is the conclusion of a ... Complex (MCC), formulated as Urocidin(TM), for the intravesical ...
... Smoke-Free Restaurants, Bars and Workplaces StatewideAUSTIN, Texas, April ... committee prepares to consider comprehensive smoke-free workplace legislation ... is launching a radio advertising campaign urging the ... all Texans from harmful secondhand smoke.(Logo: ...
... Colo., April 27 Heska Corporation (Nasdaq: HSKA ... Heska Corporation Invites You to Listen to Its ... May 5, @ 9:00 a.m. (MDT)Where: www.heska.com ... on the front page of this website)How: ...
... a complimentary resource that can assist in planning for, controlling and ... ... TX (PRWEB) April 27, 2009 -- With more than 100 deaths ... swine influenza outbreak has triggered global concern as governments everywhere scramble ...
Cached Medicine News:Health News:Donate Life California to Hold Press Conference on Organ Donation Education, April 28, 1:30 p.m., on State Capitol West Steps 2Health News:Encorium Reports Fourth Quarter and Full Year 2008 Financial Results 2Health News:Encorium Reports Fourth Quarter and Full Year 2008 Financial Results 3Health News:Encorium Reports Fourth Quarter and Full Year 2008 Financial Results 4Health News:Encorium Reports Fourth Quarter and Full Year 2008 Financial Results 5Health News:Encorium Reports Fourth Quarter and Full Year 2008 Financial Results 6Health News:Encorium Reports Fourth Quarter and Full Year 2008 Financial Results 7Health News:Encorium Reports Fourth Quarter and Full Year 2008 Financial Results 8Health News:Encorium Reports Fourth Quarter and Full Year 2008 Financial Results 9Health News:Bioniche Provides a Corporate Update 2Health News:Ad Campaign: All Texans Should Have the Right to Breathe Smoke-Free Air 2Health News:Ad Campaign: All Texans Should Have the Right to Breathe Smoke-Free Air 3Health News:Webcast Alert: Heska Corporation's Annual Meeting of Stockholders Webcast 2Health News:'Pandemic Preparedness Manual' Offers Guide to Dealing with Possible Swine Flu Pandemic 2Health News:'Pandemic Preparedness Manual' Offers Guide to Dealing with Possible Swine Flu Pandemic 3
(Date:4/20/2015)... 20, 2015 Pharmaceutical Research and Manufacturers of ... last year in the research and development (R&D) of ... majority of all biopharmaceutical R&D spending – both public ... . The new R&D numbers, the result of ... in the newly released PhRMA 2015 Biopharmaceutical ...
(Date:4/20/2015)... April 20, 2015 Stand Up To Cancer (SU2C) and ... $20 million Dream Team to attack the number one cancer ... Meeting of the American Association for Cancer Research (AACR), Scientific ... people in the United States will ... 158,040 will die from it, making lung cancer the leading ...
(Date:4/20/2015)... PALO ALTO, Calif. , April 20, 2015 ... study demonstrate positive trends in the ability of ... slow the progression of amyotrophic lateral sclerosis (ALS, ... over a 6-month treatment period. While NP001,s slowing ... of the study was not statistically significant, clinically ...
Breaking Medicine Technology:PhRMA Member Companies Invested $51.2 Billion in R&D in 2014 2PhRMA Member Companies Invested $51.2 Billion in R&D in 2014 3New SU2C-American Cancer Society Lung Cancer Dream Team Announced 2New SU2C-American Cancer Society Lung Cancer Dream Team Announced 3New SU2C-American Cancer Society Lung Cancer Dream Team Announced 4New SU2C-American Cancer Society Lung Cancer Dream Team Announced 5New SU2C-American Cancer Society Lung Cancer Dream Team Announced 6Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 2Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 3Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 4Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 5
... N.Y., March 2, 2011 Lixte ... that the company has received a $244,479.25 grant ... awarded to further development and commercialization of Lixte,s novel anti-cancer ... the Patient Protection and Affordable Care Act of 2010 to ...
... 2011 InspireMD , developer ... has expanded its MGuard production facilities to meet the ... accelerating demand for MGuard include the recent recommendation of ... be considered for PCI of highly thrombotic or SVG ...
Cached Medicine Technology:Lixte Biotechnology Holdings, Inc. Awarded Grant Under Qualifying Therapeutic Discovery Project from the U. S. Government 2InspireMD Boosts MGuard Production Capacity 2
... The SmartPulse 10.6 CO2 system was expressly ... in cosmetic surgery. A special source and ... it possible to create particular high energy ... impulses (technically known as 'top-flat shaped') allow ...
... laser is the ideal instrument for safe, ... Plus, the majority of surface lesions can ... range of scar tissue, with a minimum ... with the elimination of anaesthetics, risks and ...
... is a CO2 laser system with CW ... for dealing with all therapeutic application in ... supplies medium-to-high intensities in super-pulsed mode, designed ... surgery. It is also capable of supplying ...
... and efficient method applied to dermatological therapy ... research and development with hundreds of users, ... source, but rather a platform for future ... in pulsed-light-based technology, the most valid and ...
Medicine Products: